30-40% of people with psoriasis. The condition can cause significant disability and decreased quality of life. In recent years, apremilast, a new, oral treatment for PsA, has emerged as a potential treatment option.

Apremilast is an oral phosphodiesterase 4 inhibitor (PDE-4) and has been found to be effective in managing the symptoms of PsA. It has been studied in multiple clinical trials and is now approved for use in both the United States and Europe. Unlike other treatments for PsA, apremilast does not target the immune system directly but affects ways in which cells produce chemicals known to be involved in inflammation.

Studies have shown that apremilast can reduce the signs and symptoms of PsA, including joint pain and swelling. It can also improve physical function and reduce fatigue. Apremilast has been found to be especially beneficial in patients with active moderate to severe psoriatic arthritis. The medication can also help to reduce the need for other treatments like non-steroidal anti-inflammatory drugs (NSAIDs), reducing the risk of side effects associated with these drugs.

Apremilast has been found to be safe and well tolerated, with a low risk of serious side effects. The most common side effects reported include nausea, diarrhea, headache, and upper respiratory tract infection.

Apremilast has been shown to be a useful addition to therapeutic regimens for PsA. Its novel mechanism of action, and the fact that it is well-tolerated and associated with a low risk of serious side effects, make it an attractive treatment. It has become a valuable part of the therapeutic arsenal for managing PsA and improving patient quality of life.

Article Created by A.I.